OnabotulinumtoxinA 145 UNT [Botox]
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Drug-resistant Focal Seizure
Conditions
Drug-resistant Focal Seizure
Trial Timeline
Mar 1, 2023 → Dec 1, 2024
NCT ID
NCT05605756About OnabotulinumtoxinA 145 UNT [Botox]
OnabotulinumtoxinA 145 UNT [Botox] is a approved stage product being developed by AbbVie for Drug-resistant Focal Seizure. The current trial status is terminated. This product is registered under clinical trial identifier NCT05605756. Target conditions include Drug-resistant Focal Seizure.
What happened to similar drugs?
0 of 1 similar drugs in Drug-resistant Focal Seizure were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05605756 | Approved | Terminated |
Competing Products
6 competing products in Drug-resistant Focal Seizure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid | Novartis | Phase 2 | 42 |
| UCB0942 | UCB | Phase 2 | 27 |
| Padsevonil + Placebo | UCB | Phase 3 | 32 |
| Padsevonil | UCB | Phase 2 | 27 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 35 |
| Padsevonil | UCB | Phase 2 | 35 |